SERINA THERAPEUTICS INC. (SER) Stock Price, Quote, News and Overview
NYSEARCA:SER - NYSE Arca - US81751A1088 - Common Stock - Currency: USD
SER Quote, Performance and Key Statistics
NYSEARCA:SER (7/31/2025, 5:05:00 PM)
5.54
+0.09 (+1.65%)
The current stock price of SER is 5.54 USD. In the past month the price decreased by -9.77%. In the past year, price decreased by -39.11%.
SER Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.41 | 333.88B | ||
| AMGN | AMGEN INC | 14.21 | 158.68B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 139.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.31 | 58.89B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 51.14B | ||
| ARGX | ARGENX SE - ADR | 116.78 | 41.02B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.71 | 32.59B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.84B | ||
| INSM | INSMED INC | N/A | 20.35B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.58B | ||
| BIIB | BIOGEN INC | 8.09 | 18.76B |
Related stock screener links
About SER
Company Profile
Serina Therapeutics, Inc. operates as a pharmaceutical company, which engages in the development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 12 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Company Info
SERINA THERAPEUTICS INC.
601 Genome Way,, Suite 2001
Huntsville ALABAMA US
Employees: 12
Phone: 12563279630
SERINA THERAPEUTICS INC. / SER FAQ
What is the stock price of SERINA THERAPEUTICS INC. today?
The current stock price of SER is 5.54 USD. The price increased by 1.65% in the last trading session.
What is the ticker symbol for SERINA THERAPEUTICS INC. stock?
The exchange symbol of SERINA THERAPEUTICS INC. is SER and it is listed on the NYSE Arca exchange.
On which exchange is SER stock listed?
SER stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for SERINA THERAPEUTICS INC. stock?
5 analysts have analysed SER and the average price target is 13.26 USD. This implies a price increase of 139.35% is expected in the next year compared to the current price of 5.54. Check the SERINA THERAPEUTICS INC. stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SERINA THERAPEUTICS INC. worth?
SERINA THERAPEUTICS INC. (SER) has a market capitalization of 55.23M USD. This makes SER a Micro Cap stock.
How many employees does SERINA THERAPEUTICS INC. have?
SERINA THERAPEUTICS INC. (SER) currently has 12 employees.
What are the support and resistance levels for SERINA THERAPEUTICS INC. (SER) stock?
SERINA THERAPEUTICS INC. (SER) has a support level at 5.35 and a resistance level at 5.63. Check the full technical report for a detailed analysis of SER support and resistance levels.
Is SERINA THERAPEUTICS INC. (SER) expected to grow?
The Revenue of SERINA THERAPEUTICS INC. (SER) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SER EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SERINA THERAPEUTICS INC. (SER) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SER, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SER, evaluating the profitability, health, valuation and growth aspects
- SERINA THERAPEUTICS INC. (SER) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SERINA THERAPEUTICS INC. (SER) Sales and EPS estimates to see what analysts future expectations are.
- SERINA THERAPEUTICS INC. (SER) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SERINA THERAPEUTICS INC. (SER) Insider and Institutional Ownership to learn about the owners and their transactions.
- SERINA THERAPEUTICS INC. (SER) Stock Chart to make your own analysis
- SERINA THERAPEUTICS INC. (SER) Latest news and press-releases to stay up to date.
Does SERINA THERAPEUTICS INC. (SER) stock pay dividends?
SER does not pay a dividend.
When does SERINA THERAPEUTICS INC. (SER) report earnings?
SERINA THERAPEUTICS INC. (SER) will report earnings on 2025-08-08.
What is the Price/Earnings (PE) ratio of SERINA THERAPEUTICS INC. (SER)?
SERINA THERAPEUTICS INC. (SER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
What is the Short Interest ratio of SERINA THERAPEUTICS INC. (SER) stock?
The outstanding short interest for SERINA THERAPEUTICS INC. (SER) is 1.08% of its float. Check the ownership tab for more information on the SER short interest.
SER Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SER. When comparing the yearly performance of all stocks, SER is a bad performer in the overall market: 89.5% of all stocks are doing better.
SER Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SER. The financial health of SER is average, but there are quite some concerns on its profitability.
SER Financial Highlights
Over the last trailing twelve months SER reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 88.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -165.52% | ||
| ROE | -654.97% | ||
| Debt/Equity | 0 |
SER Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SER. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of -30.09% and a revenue growth -100% for SER